Suppression of Fas/APO-1-mediated apoptosis by mitogen-activated kinase signaling. 1998

T H Holmström, and S C Chow, and I Elo, and E T Coffey, and S Orrenius, and L Sistonen, and J E Eriksson
Turku Center for Biotechnology, University of Turku, Finland.

Jurkat T cells undergo rapid apoptosis upon stimulation of the Fas/APO-1 (CD95) receptor. We examined the role of the mitogen-activated protein kinase (MAPK) cascade as a negative regulator of Fas-mediated apoptosis. To this end, we used both physiologic and artificial activators of MAPK, all of which activate MAPK by distinct routes. MAPK activity could be efficiently elevated by two T cell mitogens, the lectin PHA and an agonistic Ab to the T cell receptor complex as well as by the type 1 and 2A phosphatase inhibitor, calyculin A, and the protein kinase C-activating phorbol ester, tetradecanoyl phorbol acetate. All these treatments were effective in preventing the characteristic early and late features of Fas-mediated apoptosis, including activation of caspases. Our results indicate that the elevated MAPK activities intervene upstream of caspase activation. The degree of MAPK activation by the different stimuli used in our study corresponds well to their potency to inhibit apoptosis, indicating that MAPK activation serves as an efficient modulator of Fas-mediated apoptosis. The role of MAPK in modulation of Fas-mediated apoptosis was further corroborated by transient transfection with constitutively active MAPK kinase, resulting in complete inhibition of the Fas response, whereas transfection with a dominant negative form of MAPK kinase had no effect. Furthermore, the apoptosis inhibitory effect of the MAPK activators could be abolished by the specific MAPK kinase inhibitor PD 098059. Modulation of Fas responses by MAPK signaling may determine the persistence of an immune response and may explain the insensitivity of recently activated T cells to Fas receptor stimulation.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005419 Flavonoids A group of phenyl benzopyrans named for having structures like FLAVONES. 2-Phenyl-Benzopyran,2-Phenyl-Chromene,Bioflavonoid,Bioflavonoids,Flavonoid,2-Phenyl-Benzopyrans,2-Phenyl-Chromenes,2 Phenyl Benzopyran,2 Phenyl Benzopyrans,2 Phenyl Chromene,2 Phenyl Chromenes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D017871 Calcium-Calmodulin-Dependent Protein Kinases A CALMODULIN-dependent enzyme that catalyzes the phosphorylation of proteins. This enzyme is also sometimes dependent on CALCIUM. A wide range of proteins can act as acceptor, including VIMENTIN; SYNAPSINS; GLYCOGEN SYNTHASE; MYOSIN LIGHT CHAINS; and the MICROTUBULE-ASSOCIATED PROTEINS. (From Enzyme Nomenclature, 1992, p277) Ca(2+)-Calmodulin-Dependent Protein Kinase,Calcium-Calmodulin-Dependent Protein Kinase,Calmodulin-Dependent Protein Kinase,Calmodulin-Dependent Protein Kinases,Multifunctional Calcium-Calmodulin-Dependent Protein Kinase,Restricted Calcium-Calmodulin-Dependent Protein Kinase,Calcium-Calmodulin-Dependent Protein Kinases, Multifunctional,Calcium-Calmodulin-Dependent Protein Kinases, Restricted,Calmodulin-Dependent Multiprotein Kinase,Calmodulin-Kinase,Cam-MPK,Multifunctional Calcium-Calmodulin-Dependent Protein Kinases,Restricted Calcium-Calmodulin-Dependent Protein Kinases,Calcium Calmodulin Dependent Protein Kinase,Calcium Calmodulin Dependent Protein Kinases, Multifunctional,Calcium Calmodulin Dependent Protein Kinases, Restricted,Calmodulin Dependent Multiprotein Kinase,Calmodulin Dependent Protein Kinase,Calmodulin Dependent Protein Kinases,Calmodulin Kinase,Cam MPK,Kinase, Calcium-Calmodulin-Dependent Protein,Kinase, Calmodulin-Dependent Protein,Multifunctional Calcium Calmodulin Dependent Protein Kinase,Multifunctional Calcium Calmodulin Dependent Protein Kinases,Multiprotein Kinase, Calmodulin-Dependent,Protein Kinase, Calcium-Calmodulin-Dependent,Protein Kinase, Calmodulin-Dependent,Protein Kinases, Calcium-Calmodulin-Dependent,Protein Kinases, Calmodulin-Dependent,Restricted Calcium Calmodulin Dependent Protein Kinase,Restricted Calcium Calmodulin Dependent Protein Kinases
D019014 fas Receptor A tumor necrosis factor receptor subtype found in a variety of tissues and on activated LYMPHOCYTES. It has specificity for FAS LIGAND and plays a role in regulation of peripheral immune responses and APOPTOSIS. Multiple isoforms of the protein exist due to multiple ALTERNATIVE SPLICING. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM. Mutations in the CD95 gene are associated with cases of autoimmune lymphoproliferative syndrome. APO-1 Antigen,Antigens, CD95,CD95 Antigens,Receptors, fas,Tumor Necrosis Factor Receptor Superfamily, Member 6,fas Antigens,fas Receptors,CD95 Antigen,Fas Cell Surface Death Receptor,TNFRSF6 Receptor,fas Antigen,APO 1 Antigen,Receptor, TNFRSF6,Receptor, fas
D019169 Jurkat Cells A CELL LINE derived from human T-CELL LEUKEMIA and used to determine the mechanism of differential susceptibility to anti-cancer drugs and radiation. Cell, Jurkat,Cells, Jurkat,Jurkat Cell

Related Publications

T H Holmström, and S C Chow, and I Elo, and E T Coffey, and S Orrenius, and L Sistonen, and J E Eriksson
April 1997, Proceedings of the National Academy of Sciences of the United States of America,
T H Holmström, and S C Chow, and I Elo, and E T Coffey, and S Orrenius, and L Sistonen, and J E Eriksson
August 1998, Experimental hematology,
T H Holmström, and S C Chow, and I Elo, and E T Coffey, and S Orrenius, and L Sistonen, and J E Eriksson
August 1998, Surgery,
T H Holmström, and S C Chow, and I Elo, and E T Coffey, and S Orrenius, and L Sistonen, and J E Eriksson
April 1998, Blood,
T H Holmström, and S C Chow, and I Elo, and E T Coffey, and S Orrenius, and L Sistonen, and J E Eriksson
October 1998, Current opinion in immunology,
T H Holmström, and S C Chow, and I Elo, and E T Coffey, and S Orrenius, and L Sistonen, and J E Eriksson
September 1995, The Journal of experimental medicine,
T H Holmström, and S C Chow, and I Elo, and E T Coffey, and S Orrenius, and L Sistonen, and J E Eriksson
January 1996, Journal of immunology (Baltimore, Md. : 1950),
T H Holmström, and S C Chow, and I Elo, and E T Coffey, and S Orrenius, and L Sistonen, and J E Eriksson
November 1998, The Journal of experimental medicine,
T H Holmström, and S C Chow, and I Elo, and E T Coffey, and S Orrenius, and L Sistonen, and J E Eriksson
December 1996, Biochemical and biophysical research communications,
T H Holmström, and S C Chow, and I Elo, and E T Coffey, and S Orrenius, and L Sistonen, and J E Eriksson
January 1999, Advances in immunology,
Copied contents to your clipboard!